Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026

First clinical data for OAP-101, built on proprietary OmniAntigen™ Platform (OAP)OAP enables systematic immune reprogramming therapy (XIRT™) to overcome resistance of cold solid tumors to current ...

IFx 2.0 Market Size and Sales Forecast in the 7MM - 2034 | Phase III Momentum and Checkpoint Inhibitor Combinations Expand Commercial Potential

Late-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns.Dublin, Oct. 13, 2026 (GLOBE ...
BioSpace

Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026

INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational ...
BIOENGINEER

Immunotherapy Added to Standard Treatment Shows Early Promise Against Aggressive Brain Tumors

A retrospective study of 25 patients suggests that adding the anti-PD-1 antibody pucotenlimab to concurrent radiochemotherapy produced tumor responses and favorable survival figures in adults with ...

Homens costumam descobrir câncer de mama em estágio mais avançado

Levantamento alerta para necessidade de observar sinais da ...